| |
Tuesday, February 7, 2023 | 11am ET / 8am PT This session will focus upon understanding your knowns and unknowns, best practices for mitigating risk, and addressing the specific drug supply challenges commonly associated with complex trial designs. Register now.
|
|
Today's Big NewsFeb 1, 2023 |
|
Thursday, Feb 16, 2023 | 2:00pm ET During this session, NetApp will explore how data is leveraged in Life Sciences to create a data fabric strategy that’s aligned to your business. This includes how to detailing each cycle of the data foundation for data governance and quality, data accessibility, data platforms, data as a service, data as a business, predictive intelligence, optimizing how solutions are managed across the data lifecycle, and more. Register now.
|
|
| By Angus Liu As the incoming chair of the industry trade group PhRMA, Novartis CEO Vas Narasimhan has ideas about how the industry should respond to the consequential U.S. drug pricing law. |
|
|
|
By Max Bayer More companies laid off staff last month than in January 2022, driven by trims at billion-dollar Big Pharmas and smaller biotechs that had to downsize for the second time in less than a year. |
By Heather Landi As part of its new virtual primary care offering, CVS Health is expanding telehealth-based mental health services to include appointments with licensed therapists and psychiatrists. |
By Andrea Park 2022 was the year that diagnostics makers saw their previously sky-high COVID-19 test sales come crashing back down to earth—but the lucky ones were still able to eke out some overall revenue growth for the year. |
|
Tuesday, Feb 28, 2023 | 11:00am ET The heavy lifting for the pharmaceutical industry to comply with the November 2023 DSCSA go-live date is still ongoing. One item now finalized is to ensure that the required data exchange through the supply chain is only done with trusted, authorized, and registered trading partners. Join us for this discussion to stay up-to-date on this important legislation and be prepared for compliance. Register now.
|
|
By Angus Liu As Novartis prepares to spin off Sandoz to become a pure-play innovative medicines company, several of the Swiss pharma’s new medicines have started taking diverging launch trajectories. |
By Gabrielle Masson Evelo Biosciences’ lead asset has flunked a phase 2 trial in eczema after an unusually high placebo response rate was reported in at least three of four cohorts. The data drop comes as the biotech manages to hang on to CEO Simba Gill, Ph.D., but initiates layoffs. |
By Conor Hale Miromatrix is currently awaiting a green light from the FDA to launch a phase 1 human study, after the agency handed down a clinical hold and requested additional data. |
By Paige Minemyer Humana has named a new leader for its growing CenterWell business, the company announced early Wednesday. The news was released alongside its Q4 earnings. |
By Eric Sagonowsky With GSK’s consumer healthcare spinoff now in the rearview mirror, the company is operating as the lean, innovative medicines-focused drugmaker CEO Emma Walmsley envisioned years ago. And 2022’s financial performance shows the company’s promise. |
By James Waldron Once seen as a bright hope for immuno-oncology, the reputation of anti-TIGIT checkpoint inhibitors has yet to recover from the double whammy of trial flops that Roche experienced last year. So you can perhaps forgive fellow Swiss drugmaker Novartis for not putting its own TIGIT ambitions front and center. |
By Andrea Park Stryker’s net earnings also got a boost. After raking in just below $2 billion in 2021, profits increased by more than 18% a year later, coming out to nearly $2.4 billion in 2022. |
By Frank Diamond The number of individuals with long COVID seems to be shrinking, according to an analysis of CDC data by the Kaiser Family Foundation. Nonetheless, uncertainty about the condition abounds. |
Fierce podcastsDon't miss an episode |
| | In this week's episode of "Podnosis," we discuss post-pandemic hospital financing and what leaders will need to focus on this year and beyond. We also talk about the importance of value-based care and how to account for equitable care. |
|
|---|
|
|
|
The global demand for biologics is projected to increase considerably by 2030, but the challenges, risks, and costs are also growing. For pharma companies looking to bring a new biologic to market, meeting clinical trial milestones can be difficult. To access important insights, download this executive summary now.
|
|
| WhitepaperThis paper explores the cost drivers behind gene therapies and how they are likely to evolve in the coming years. Sponsored by: Blue Matter |
| WhitepaperExploring the biology of G Protein-Coupled Receptors (GPCRs) and outlining a novel approach for developing therapeutics against previously undruggable GPCRs Sponsored by: Orion Biotechnology |
| WhitepaperLearn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| WhitepaperRCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
| Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
